Movement Alert｜CVS Health Rises 3.29% in Regular Trading, Multiple Banks Raise Targets as Formulary Expansion Boosts Outlook

Market Focus06-04 22:25

On June 4, CVS Health rose 3.29% in regular trading, trading at $94.185/share, with trading volume of $319 million. Multiple positive catalysts converged to drive the stock higher.

On the analyst front, Morgan Stanley raised its target price on CVS Health from $106 to $111 while maintaining an outperform rating. Truist also lifted its target from $102 to $108, maintaining a buy rating. The average analyst consensus target now stands at $101.71, with an overweight rating.

On the business front, CVS Caremark, the company's pharmacy benefit management division, announced it will restore coverage of Eli Lilly's weight-loss injection Zepbound as a preferred option in its commercial formularies starting October 1. The unit will also add Lilly's new daily oral weight-loss drug Foundayo. The company stated these moves resulted from successful negotiations with manufacturers to lower costs, aiming to provide broader GLP-1 drug access for plan members. Market participants expect the expanded formulary to enhance CVS Caremark's competitive positioning in the pharmacy benefit management space.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1106424171?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 22:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106424171","market":"us","top_or_hot":-1,"title":"Movement Alert｜CVS Health Rises 3.29% in Regular Trading, Multiple Banks Raise Targets as Formulary Expansion Boosts Outlook","media":"Market Focus","content":"<p><p>On June 4, CVS Health rose 3.29% in regular trading, trading at $94.185/share, with trading volume of $319 million. Multiple positive catalysts converged to drive the stock higher.</p><p>On the analyst front, Morgan Stanley raised its target price on CVS Health from $106 to $111 while maintaining an outperform rating. Truist also lifted its target from $102 to $108, maintaining a buy rating. The average analyst consensus target now stands at $101.71, with an overweight rating.</p><p>On the business front, CVS Caremark, the company's pharmacy benefit management division, announced it will restore coverage of Eli Lilly's weight-loss injection Zepbound as a preferred option in its commercial formularies starting October 1. The unit will also add Lilly's new daily oral weight-loss drug Foundayo. The company stated these moves resulted from successful negotiations with manufacturers to lower costs, aiming to provide broader GLP-1 drug access for plan members. Market participants expect the expanded formulary to enhance CVS Caremark's competitive positioning in the pharmacy benefit management space.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CVS Health Rises 3.29% in Regular Trading, Multiple Banks Raise Targets as Formulary Expansion Boosts Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CVS Health Rises 3.29% in Regular Trading, Multiple Banks Raise Targets as Formulary Expansion Boosts Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-04 22:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 4, CVS Health rose 3.29% in regular trading, trading at $94.185/share, with trading volume of $319 million. Multiple positive catalysts converged to drive the stock higher.</p><p>On the analyst front, Morgan Stanley raised its target price on CVS Health from $106 to $111 while maintaining an outperform rating. Truist also lifted its target from $102 to $108, maintaining a buy rating. The average analyst consensus target now stands at $101.71, with an overweight rating.</p><p>On the business front, CVS Caremark, the company's pharmacy benefit management division, announced it will restore coverage of Eli Lilly's weight-loss injection Zepbound as a preferred option in its commercial formularies starting October 1. The unit will also add Lilly's new daily oral weight-loss drug Foundayo. The company stated these moves resulted from successful negotiations with manufacturers to lower costs, aiming to provide broader GLP-1 drug access for plan members. Market participants expect the expanded formulary to enhance CVS Caremark's competitive positioning in the pharmacy benefit management space.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CVS","symbol_name":"西维斯健康","start_time":0,"source_url":"","article_id":"1106424171","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106424171","pubTimestamp":1780583123,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 4, CVS Health rose 3.29% in regular trading, trading at $94.185/share, with trading volume of $319 million. Multiple positive catalysts converged to drive the stock higher.On the analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CVS":"西维斯健康"},"translate_title":"动向提示|CVS Health常规交易涨3.29%多家银行上调目标因处方集扩张提振前景","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVS":1},"content_text":"On June 4, CVS Health rose 3.29% in regular trading, trading at $94.185/share, with trading volume of $319 million. Multiple positive catalysts converged to drive the stock higher.On the analyst front, Morgan Stanley raised its target price on CVS Health from $106 to $111 while maintaining an outperform rating. Truist also lifted its target from $102 to $108, maintaining a buy rating. The average analyst consensus target now stands at $101.71, with an overweight rating.On the business front, CVS Caremark, the company's pharmacy benefit management division, announced it will restore coverage of Eli Lilly's weight-loss injection Zepbound as a preferred option in its commercial formularies starting October 1. The unit will also add Lilly's new daily oral weight-loss drug Foundayo. The company stated these moves resulted from successful negotiations with manufacturers to lower costs, aiming to provide broader GLP-1 drug access for plan members. Market participants expect the expanded formulary to enhance CVS Caremark's competitive positioning in the pharmacy benefit management space.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106424171","isCrawlerRequest":true}